Dr. Walmsley serves as General Partner of Logos Capital and co-manages the firm’s private and structured public investment efforts. Prior to co-founding Logos, Dr. Walmsley was a Principal and Portfolio Manager of the Vantage crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director while building and launching multiple companies, including BlueRock Therapeutics (acquired by Bayer AG) and Akero Therapeutics. He was also the head of business development for Jecure Therapeutics through its acquisition by Genentech, a subsidiary of Roche. Dr. Walmsley has a